Blog Entry List
Federal support ending for Resource Utilization Groups III and IV on federally required assessments for patients effective Oct. 1, 2023.
Pegfilgrastim-FpgkInjection, for Subcutaneous Use (Stimufend®) HCPCS Code J3590 - Billing Guidelines
Effective with date of service Jan. 23, 2023, the Medicaid and NC Health Choice programs cover pegfilgrastim-fpgk
Effective with date of service Jan. 20, 2023, the Medicaid and NC Health Choice programs cover fecal microbiota, live - jslm suspension, for rectal use (Rebyota).
Effective with date of service Jan. 30, 2023, the Medicaid and NC Health Choice programs cover bendamustine hydrochloride injection, for intravenous use (Baxter).
Effective with date of service Jan. 27, 2023, the Medicaid and NC Health Choice programs covers ublituximab-xiiy injection, for intravenous use (Briumvi)
Effective immediately, all providers must use the Electronic Visit Verification vendor of their choice for every home health visit.
In compliance with federal requirements, beneficiary consent is required for all voluntary sterilizations.
Effective April 1, 2023, NC Medicaid covers ambulatory blood pressure monitoring. This helps confirm or exclude suspected hypertension.
Clarifies requirements related to Research Based-Behavioral Health Treatment and Specialized Consultative Services and New Taxonomy
Providers are required to make adequate provision for return of any money incorrectly collected
CCP 1A-39 has been updated to reflect changes in 1905(a) of the Social Security Act
Provider reverification, Tailored Plans start date Oct. 1, upcoming key milestones, playbook updates, billing requirement modifications and more.
The waiver has received approval for another five years through Feb. 29, 2028.
Implementation guidelines reflect the Tailored Plan launch date of Oct. 1, 2023.